Evolus

98 articles about Evolus

• Evolus to Participate in Three Upcoming Investor Conferences

  9/8/2020

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in three upcoming virtual investor conferences. Event : Wells Fargo 2020 Virtual Healthcare Conference Format: Virtual Fireside chat Date : Thursday, September 10, 2020 Time: 1:20 – 1:50pm ET     Event : H

• Evolus Reports Second Quarter 2020 Results and Provides Business Update

  8/10/2020

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, reported financial results for the second quarter ended June 30, 2020 and provided a business update.

• Evolus to Report Second Quarter 2020 Financial Results and Provide a Business Update on Monday, August 10, 2020

  7/27/2020

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2020 financial results and provide a business update on Monday, August 10, 2020 after the close of the U.S. financial markets.

• Evolus Strengthens Balance Sheet; Secures $40 Million InvestmentPro Forma Cash¹ Position of $125 Million at June 30, 2020

  7/6/2020

  Evolus, Inc. announced that its strategic partner, Daewoong Pharmaceutical Co. Ltd., will invest $40 million in a five-year, unsecured, subordinated, 3% convertible note in the Company at a conversion price of $13.00, which represents a 144% premium to the closing price on July 6, 2020.

• Evolus Reports First Quarter 2020 Results and Provides Business Update

  5/11/2020

  Evolus, Inc. reported financial results for the first quarter ended March 31, 2020 and provided a business update, including the impact of the COVID-19 pandemic.

• Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020

  5/6/2020

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that it will report its first quarter 2020 financial results and provide a business update on Monday, May 11, 2020 after the close of the U.S. financial markets.

• Evolus Provides Strategic Business Update

  4/16/2020

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a pre-emptive plan to support the U.S. aesthetic neurotoxin market in light of the COVID-19 pandemic. “We are in unprecedented times. As a result of COVID-19, social norms have evolved and the reliance on technology has accelerated. Since launch, the combination of our experienced sal

• Evolus Provides Update on International Trade Commission (ITC) CaseCompany Remains Confident in its Intellectual Property and the Overall Merits of the Case

  3/4/2020

  Evolus, Inc. (NASDAQ: EOLS) today provided the following statement: “In several media reports this week, Medytox has made comments on the International Trade Commission (ITC) case, which Evolus believes are speculative and intended to create confusion in the U.S. market ahead of the ITC Judge’s initial determination in June 2020 and the ITC’s final determination, which is targeted for October 2020.

• Evolus to Participate in Barclays 2020 Global Healthcare Conference

  3/3/2020

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that management will be participating in the Barclays 2020 Global Healthcare Conference in Miami, Florida.

• Evolus Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update

  2/25/2020

  Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2019.

• Evolus to Participate in 9th Annual SVB Leerink Global Healthcare Conference

  2/13/2020

  NEWPORT BEACH, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 9 th Annual SVB Leerink Global Healthcare Conference in New York, NY. Event :   9 th Annual SVB Leerink Global Healthcare Conference Format:   Presentation & 1x1 Meetings Date :   Wednesday, February 26,

• Evolus to Report Fourth Quarter and Full Year 2019 Financial Results and Provide a Business Update on Tuesday, February 25, 2020

  2/12/2020

  NEWPORT BEACH, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and full year 2019 financial results and provide a business update on Tuesday, February 25, 2020 prior to open of the U.S. financial markets. Management will host a conference call and live webcast to discuss Evolus’ financial results at 8:00 a.m.

• Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery

  1/27/2020

  Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4

• Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue

  1/9/2020

  Evolus, Inc. announced its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2019 and cash position at December 31, 2019.

• Evolus Announces Pricing of Public Offering of Common Stock at $13.00 per share

  11/7/2019

  Evolus, Inc. announced the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions.

• Evolus Announces Proposed Public Offering of Common Stock

  11/6/2019

  Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

• Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update

  11/4/2019

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, provides a business update and reports financial results for the third quarter ended September 30, 2019.

• Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019

  10/28/2019

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its third quarter 2019 financial results and provide a business update on Monday, November 4, 2019 prior to open of the U.S. financial markets.

• Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva™ (prabotulinumtoxinA) to Customers in Canada

  10/16/2019

  Evolus, Inc. (NASDAQ: EOLS) and Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic equipment and consumables, today announced the first shipment of Nuceiva™ (prabotulinumtoxinA) in Canada.

• ALPHAEON Corporation sells 4 million shares in Evolus Inc.

  5/15/2019

  ALPHAEON Corporation announced that it has agreed to sell approximately 4.0 million shares of common stock in Evolus, Inc. in an underwritten public offering with Morgan Stanley acting as sole underwriter for the offering.